Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flexyn2a Challenge Study
NCT02646371Phase 2Completed
- Sponsor
- LimmaTech Biologics
- Start
- Dec 2015
- Primary completion
- Sep 2016
- Modality
- Split/Subunit Vaccines, Live Attenuated Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in shigellosis comparing Flexyn2a with Placebo (2 arms). Primary endpoint: Attack Rate of Shigellosis. Started Dec 2015; status: completed.
02
Drugs
Flexyn2a
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT02646371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02646371.